ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2 Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. January 02, 2019
ProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher Syndrome Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. March 17, 2021
ProQR Announces the Grant of two Key Patents, protecting QR-010 for Cystic Fibrosis in the US and EU Press release Key Updates April 03, 2017
ProQR Announces Enrollment Has Started in Global Phase 1b Study of QR-010 in Cystic Fibrosis Patients Press release LEIDEN, the Netherlands, June 26, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. June 26, 2015
ProQR Announces Clinical Data Presentations and Investor & Analyst Event at NACFC Press release LEIDEN, the Netherlands, Sept. 27, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. September 27, 2016
ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. February 16, 2021
ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa Press release … to receive ODD from the FDA and EMA. A first-in-human clinical trial of QR-313 is expected to be initiated in 2018, with … November 29, 2017
ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board Press release Key Updates November 09, 2017
ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. September 09, 2019
ProQR Receives Orphan Drug Designation from FDA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa and will Present Data at two Scientific Conferences Press release … receive ODD in the U.S. The Company will be presenting pre-clinical data for QR-313 at two European scientific … is designed for topical administration. A first-in-human clinical trial of QR-313 will be initiated in 2018. Clinical data from … September 19, 2017